Camlin Fine Sciences has issued a postal ballot notice seeking member approval for the appointment of Mr. Atul Pradhan as a non-executive independent director. The resolution requires passage via remote e-voting under Section 110 of the Companies Act, 2013.

The Board approved the appointment following a recommendation from the Nomination and Remuneration Committee. Mr. Pradhan, aged 62, will serve a five-year term commencing September 11, 2026. He holds no shares in the company and is unrelated to existing directors or key managerial personnel.

Voting Process Details

Shareholders eligible to vote are those registered on the company’s books as of September 11, 2026. National Securities Depository Limited (NSDL) will facilitate the e-voting process. The voting window opens on September 17, 2026, at 9:00 am and closes on October 16, 2026, at 5:00 pm.

Director Profile

Mr. Pradhan brings extensive governance experience, including prior roles as Head of Management Consulting at KPMG India and partner at Transfolign Consulting LLP. He holds an MBA and a Diploma in Electronics and Electrical Communication Engineering.

His remuneration will consist of fees for board and committee meetings, expense reimbursements, and potential profit-related commissions within limits stipulated by Section 197 of the Companies Act, 2013. He currently serves as a director in Lead Angels Association for Entrepreneurship Development and Translytics Business Services Private Limited.

Camlin Fine Sciences reported a consolidated net loss of ₹336.22 million for the quarter ended June 30, 2026, widening significantly from a net loss of ₹106.81 million in the corresponding quarter of the previous year. The deterioration in profitability was primarily driven by significant foreign exchange losses of ₹83.69 million and an exceptional item of ₹108.80 million related to an insurance claim shortfall, which offset a robust 27.50% year-on-year growth in consolidated revenue from operations to ₹5,198.79 million.

The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Kalyaniwalla & Mistry LLP. The company also disclosed that it has restructured its segment reporting to reflect three distinct business units: Specialty Ingredients, Aroma, and Performance Chemicals & Others.

Consolidated revenue from operations surged to ₹5,198.79 million from ₹4,077.21 million in Q1FY26. Standalone revenue also grew 16.20% to ₹2,224.86 million from ₹1,914.38 million in the prior year period. However, total expenses increased disproportionately. Standalone total expenses rose to ₹2,425.60 million from ₹2,115.04 million, while consolidated expenses climbed to ₹5,437.65 million from ₹4,184.18 million. This cost inflation resulted in a pre-tax loss from continuing operations of ₹322.59 million on a consolidated basis, compared to a loss of ₹31.79 million in the same quarter last year.

Key Financial Metrics

The following table summarises the standalone and consolidated financial performance for the quarter:

Segment Performance

The Specialty Ingredients segment remained the primary revenue driver, contributing ₹4,013.17 million to gross segment revenue, up from ₹2,936.08 million in Q1FY26. The Aroma segment saw robust growth, with revenue jumping to ₹774.07 million from ₹566.88 million. Performance Chemicals & Others contributed ₹1,748.90 million. While Specialty Ingredients generated a positive segment result of ₹254.66 million, the Aroma segment incurred a loss of ₹33.81 million, and Performance Chemicals & Others posted a loss of ₹44.41 million.

Management highlighted that the Aroma segment's loss was due to low capacity utilization during the cautious ramp-up of ethyl vanillin production. Approximately 350 metric tons of ethyl vanillin and 200 metric tons of methyl vanillin were sold. With a total capacity of 6,000 tons and an achievable rate of 5,000 tons, the company estimates annual production of around 3,000 tons for FY27, representing 60-70% utilization. Management expects the Aroma segment to turn positive in Q2FY27 as capacity utilization improves and the mix shifts back to higher-margin methyl vanillin.

Working Capital and Debt

Gross debt stood at ₹6,400 million as on June 30, 2026, down from ₹6,700 million as on March 31, 2026, primarily due to prepayments on long-term loans from IFC and EXIM Bank for the vanillin plant. However, management indicated that working capital requirements are elongating due to geopolitical disruptions affecting shipping routes (Hormuz Strait and Red Sea issues) and slower customer recoveries. The company may need to raise additional credit lines of ₹1,000 million to ₹2,000 million during the year to support working capital needs for projected revenue growth.

What the Numbers Show

The widening consolidated loss and sharp EBITDA contraction are largely attributable to non-operational factors rather than core operational inefficiencies. The company recorded a foreign exchange loss of ₹83.69 million under finance costs, significantly impacting the bottom line. Additionally, an exceptional item of ₹108.80 million was recognised due to a shortfall in the settlement of an insurance claim regarding a fire incident at CFS Do Brasil Industria in February 2026. These one-off charges masked the underlying revenue growth, indicating that the operational engine is expanding even as external financial headwinds compress net margins.

Other Developments

The company completed the acquisition of minority stakes in Vinpai S.A., increasing its holding to 95.41% following an open offer that closed on July 6, 2026. The transaction involved the transfer of 501,842 equity shares for ₹194.63 million. Furthermore, management confirmed that the loss from machinery and inventory due to a fire at the Diphenol manufacturing unit in Dahej on May 23, 2026, amounting to ₹67.03 million, is fully covered by insurance claims, with no residual loss expected. The liquidation process of CFS Europe SpA continues, with legal expenses of ₹2.50 million booked under discontinued operations.